ImpACT Therapeutics Successfully Closes RMB 400 Million Series D+ Financing to Advance Synthetic Lethality Oncology Pipeline

VCBeat learns first，An Innovative Drug R&D Company Focused on the Mechanisms of Synthetic Lethality in Oncology—Nanjing IMPACT Therapeutics Co., Ltd. (hereinafter referred to as “IMPACT Therapeutics”), announced the successful completion of a RMB 400 million Series D+ financing round. This round of financing was led byGTJA Investment GroupandXicheng JinruiCo-lead investment,Yangzhou Guojin GroupandGu Yu Nan GeParticipating in this investment, existing shareholdersLilly Asia VenturesandXiamen C&D Emerging InvestmentContinued Escalation in This Round.Zhoudu CapitalServed as the financial advisor for this round of financing.

IMPACT Therapeutics is dedicated to the research and development of world-class, innovative targeted anticancer drugs with independent intellectual property rights, with a focus on synthetic lethality mechanisms. Building on its independently developed products targeting the DNA damage response (DDR) pathway, the company has established one of the most comprehensive DDR product portfolios among global biopharmaceutical companies and is progressively expanding into additional novel synthetic lethality targets. The company’s pipeline includes the PARP inhibitor senaparib, the WEE1 inhibitor IMP7068, the ATR inhibitor IMP9064, the PARP1-selective inhibitor IMP1734 (co-developed with Eikon Therapeutics in the United States), as well as multiple other DDR target inhibitors.

Dr. Cai Suixiong, CEO of IMPACT Therapeuticsstated: “We are pleased to announce the successful completion of our Series D+ financing. We extend our gratitude to both new and existing shareholders for their support and trust in IMPACT Therapeutics. The proceeds from this round will accelerate the commercialization of senaparib, sustain the clinical development of multiple compounds—including the global development of a PARP1-selective inhibitor—and advance the R&D of several early-stage preclinical projects. We firmly believe that, with the steadfast support of our distinguished investors, senaparib, which possesses best-in-class potential, will reach more ovarian cancer patients at an accelerated pace by leveraging Huadong Medicine’s extensive marketing network and professional academic promotion expertise as our commercialization partner. We also look forward to witnessing the breakthrough potential of additional innovative candidate drugs targeting synthetic lethality, a key focus area for IMPACT Therapeutics, in subsequent clinical validations.”

Yu Jianlin, Deputy General Manager of GTJA Investment Groupstated: “We are delighted to participate in this round of financing for IMPACT Therapeutics. Leveraging its outstanding independent R&D capabilities, IMPACT Therapeutics has built one of the most comprehensive synthetic lethality product portfolios among global biopharmaceutical companies. Its core product, senaparib, has demonstrated best-in-class potential in pivotal clinical trials, and its New Drug Application (NDA) has been submitted and accepted by the National Medical Products Administration (NMPA). As a professional investment institution focused on the healthcare sector, GTJA Investment Group will fully support IMPACT Therapeutics’ drug development efforts. We look forward to seeing IMPACT’s products benefit more cancer patients through the team’s continued efforts, thereby truly addressing the unmet clinical needs of the broad cancer patient population.”

Chen Leiwen, Managing Partner of Xicheng Jinrui“The company possesses unique source-innovation research technologies and platforms, along with a profound understanding of the mechanisms underlying synthetic lethality-targeted therapies. Last year, IMPACT Therapeutics out-licensed overseas rights for products in its pipeline to Eikon Therapeutics and established a series of commercialization partnerships with Huadong Medicine, demonstrating the team’s exceptional capabilities in drug R&D and execution. As the biopharmaceutical sector is a national strategic emerging industry, we adhere to the philosophy of long-term value investment and remain firmly confident in the company’s team and product pipeline. We hope that this round of financing will accelerate the market launch of the company’s promising drugs, thereby benefiting a broad patient population.”

GTJA Investment Group was established in Shenzhen in 2001, pioneering the "thematic industry investment" model within the sector. Focusing on investments in the healthcare and medical industry, the firm adopts strategic equity investment as its core approach, covering all stages including M&A, private equity (PE), venture capital (VC), and angel investing. With assets under management exceeding RMB 20 billion, GTJA has invested in more than 160 companies and facilitated the successful listing of 36 enterprises. Committed to investing in outstanding healthcare companies worldwide, GTJA bridges Chinese momentum with global capital and medical enterprises, assisting entrepreneurs in building great companies.

Beijing Xicheng Jinrui Equity Investment Fund Management Co., Ltd. was established in 2018 as a market-oriented professional investment institution with state-owned capital background, jointly initiated by Beijing Financial Street Capital Operation Group Co., Ltd., China State-Owned Enterprise Structural Adjustment Fund Co., Ltd., and China Reform Holdings Corporation Ltd. It focuses on high-quality enterprises in fields such as digitalization, intelligence, carbon neutrality, and healthcare.

Yangzhou Guojin Investment Group Co., Ltd. was established on November 21, 2022, as a major initiative by the Yangzhou Municipal Committee of the Communist Party of China and the Yangzhou Municipal People’s Government to advance financial reform and innovation and accelerate the development of the local financial industry. As a municipal-level key financial holding platform funded by the municipal government, Guojin Group has a registered capital of RMB 6 billion. It will make equity investments in financial institutions on behalf of the government, manage government-guided funds, leverage additional financial capital, and inject new momentum into the high-quality economic and social development of Yangzhou City. The Group’s core business activities include investments in the financial sector, quasi-financial investments, fund investment and management, industrial investment, and capital market intermediary services.

The Group’s strategic positioning is defined as follows: to strive to become a comprehensive financial enterprise that the municipal party committee and municipal government can rely on for building a renowned city and driving economic development. Specifically, the Group aims to: serve as the “dual engines” of urban operation and development, contributing financial strength to the transformation of urban development momentum; act as a “collaborator” with fiscal authorities, taking proactive measures in resolving local government debt and advancing inclusive finance; function as an “ally” in strengthening county and district economies, providing capital support for the secondary entrepreneurship of industrial parks and industrial upgrading; serve as the “primary bridge” for connecting financial resources, fully leveraging leverage advantages in financing; and act as a “facilitator” of industrial transformation and upgrading, innovating models in investment promotion and industrial agglomeration.

Gu Yu Nan Ge is a limited partnership enterprise registered in China, primarily engaged in technology promotion and application services. The general partner of Gu Yu Nan Ge is Shanghai Yuyuan Yong Management Consulting Co., Ltd.

Lilly Asia Ventures (LAV) is a premier venture capital fund dedicated to investing in the life sciences and healthcare sectors. Headquartered in Shanghai, China, it maintains offices in Hong Kong, China, and Silicon Valley, USA. The fund’s long-term vision is to build great companies that combat diseases and improve human health through breakthrough products, and to serve as a trusted partner for outstanding entrepreneurs seeking smart capital.

Xiamen C&D Emerging Industry Equity Investment Co., Ltd. was established in 2014 as one of the five major business segments of Xiamen C&D Group Co., Ltd. (a Fortune Global 500 company). Specializing in equity investment in emerging industries, the company is committed to becoming a leading equity asset management institution in China’s emerging sectors, driven by a dual-engine strategy encompassing both asset and capital sides. C&D Emerging Investment focuses on investment opportunities related to the innovation and growth of national strategic emerging industries. Adopting a multi-strategy approach centered on “P+D+S,” it prioritizes three key sectors: healthcare, advanced manufacturing, and TMT/consumer goods, thereby facilitating superior development for more emerging enterprises.

Senaparib, a novel and highly potent PARP1/2 inhibitor independently developed by IMPACT Therapeutics, features a unique molecular structure that ensures excellent target selectivity and a broad safety window. The Phase III registrational clinical study (FLAMES) of senaparib for first-line maintenance treatment in the overall population with advanced ovarian cancer has met its primary endpoint. In August 2022, the fixed-dose combination capsule of senaparib and temozolomide (TMZ) for the treatment of adult patients with small cell lung cancer (SCLC) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). In August 2023, the National Medical Products Administration accepted the New Drug Application (NDA) for senaparib in China.